Pacific Biosciences' 2026 Q2 Call Flags Contradictions in Vega Transition Dynamics, Margin Recovery Timelines

Date of Call: Aug 5, 2026

Financials Results

• Revenue: $39M, compared to $39.8M in Q2 2025 (roughly flat YOY)
• EPS: Non-GAAP net loss of $0.14 per share, compared to $0.13 per share loss in Q2 2025
• Gross Margin: 36% (non-GAAP), compared to 38% in Q2 2025

Guidance:

• Revenue for 2026 lowered to $155M-$165M.
• Non-GAAP gross margin for 2026 expected in range of 35%-37%.
• Cash expected to end year at $175M-$185M.
• Non-GAAP operating expenses expected $215M-$220M.
• Cash flow breakeven now expected in 2028 vs. end of 2027 prior.

Business Commentary:

Leadership Transition and Strategic Focus:

• PACBio announced a leadership transition with Mark Van Ollen assuming the role of President and CEO, effective immediately.
• The change aims to leverage Van Ollen's deep understanding of genomics and clinical markets to drive the company's strategy forward, focusing on scaling clinical engagement and high-throughput sequencing solutions.

Spark Next Chemistry Rollout and Impact:

• The full global commercial rollout of PACBio's new Spark Next Chemistry has been launched, with over a third of the install base opting into new consumer software in June.
• Spark Next provides a 30% increase in sequencing throughput per run and enables each smart cell to be used up to three times, enhancing economics and enabling larger projects, expected to be a significant driver of volume in the second half of the year and beyond.

Revenue and Segment Performance:

• PACBio reported $39 million in second quarter revenue, a slight increase from Q1 but roughly flat year-over-year.
• Revenue was driven by growing consumables and new revenue and Vega placements, although offset by lower-priced strategic placements and funding constraints affecting academic and government sectors.

Regional and Market Dynamics:

• The EMEA region showed significant growth with a 52% increase in revenue, driven by clinical adoption and a major strategic multi-system placement.
• In contrast, the Americas experienced a slight decline due to NIH and broader academic funding uncertainty, while Asia-Pacific saw a 45% decrease, impacted by the conclusion of a population sequencing program and funding headwinds.

Cost Management and Margin Outlook:

• Non-GAAP gross margin for the second quarter was 36%, down from 38% in the prior year, due to compute cost inflation and lower manufacturing volumes.
• The company is implementing a restructuring plan to reduce headcount by approximately 40 employees, aiming to lower operating expenses and improve cost structure alignment with strategic priorities.

Sentiment Analysis:

Overall Tone: Positive

• Mark Van Ollen: 'I'm energized by the multiple catalysts in front of us and confident in what's ahead...' and 'The catalysts we've built toward... are now convergent.' Management highlights strong Spark Next customer enthusiasm, new multi-system orders, and clinical adoption momentum, despite lowering revenue guidance due to transition headwinds.

Q&A:

• Question from Kyle Mixon (Canaccord Genuity): On the Revio and Vegas placements, how many are clinical customers, and how is that shaping the future?
  Response: Most Revio placements in Q2 were to new clinical customers; Vegas placements were majority to new customers, with health labs showing momentum.

• Question from Subbu Nambi (Guggenheim): What is the expected sequential pull-through for Revio consumables in the second half?
  Response: Expect consumables to remain flat sequentially through the next quarter as customers transition inventory, then scale through the back half of the year with Spark Next adoption.

• Question from Jack Meehan (Oppenheimer Research): Can you discuss memory supply, 2027 headwinds, and when multi-use smart cells will improve gross margins?
  Response: Memory supply is secured through end of 2026; persistent memory and Vega transition costs are headwinds, but Spark Next ramp in H2 2026 will help offset.

• Question from Mason Carrico (Stevens): Are early signs showing the 30% cost reduction from Spark Next is expanding sample volumes to offset pricing?
  Response: Demand is strong with a third of install base on software; expect volume growth and margin expansion as inventory transitions and validation completes in H2.

• Question from Dan Brennan (TD Cowen): Will Vega consumables face a similar transition phase as Revio with Spark Next launch?
  Response: No significant dynamic expected for Vega due to lower utilization; Spark Next on Vega will expand application set and drive utilization via higher throughput.

• Question from David Westenberg (Piper Sandler): What advantages does PacBio's long-read tech offer in the multi-omics shift, and what are biopharma partners seeking?
  Response: PacBio's technology comprehensively captures repeat expansions, structural variation, methylation, and RNA isoforms, making it attractive for multi-omics and AI model training.

• Question from Tycho Peterson (Jefferies): Why was guidance lowered despite positive signals like Spark Next launch and new customer orders?
  Response: Guidance reflects headwinds from Spark Next transition and elevated compute/memory costs; lowered cash breakeven to 2028 accounts for these uncertainties.

• Question from Luke Sergant (Barclays): What drove the commercial reorganization, and what will the new structure focus on?
  Response: Restructuring aligns marketing and sales to sharpen focus on clinical market opportunity, expanding the successful model seen in EMEA.

Contradiction Point 1

Vega Consumables Transition Dynamics

Contradiction on whether Vega launch will involve inventory burn or directly expand applications.

Jack Meehan (Oprah Research) - Jack Meehan (Oprah Research)

2026Q2: The Spark Next ramp in H2 2026 is expected to offset persistent memory and Vega manufacturing transition costs. The company anticipates returning to gross margin improvement in 2027. - Jim Gibson(CFO)

Regarding memory supply and pricing, how much is locked in for H2 2027, what are the incremental headwinds if spot pricing holds, and when will multi-use Smart Cells start positively impacting gross margins? - Dan Brennan (TD Cowen)

2026Q2: No similar dynamic expected for Vega due to its lower utilization compared to Revio. Spark Next on Vega will instead expand application sets by offering higher throughput... enabling larger panels, amplicon sets, and occasional whole genomes. - Mark Van Ollen(CEO)

Contradiction Point 2

Gross Margin Improvement Timeline

Contradiction on when gross margin expansion from Spark Next will become pronounced.

Jack Meehan (Oprah Research) - Jack Meehan (Oprah Research)

2026Q2: The Spark Next ramp in H2 2026 is expected to offset persistent memory and Vega manufacturing transition costs. The company anticipates returning to gross margin improvement in 2027. - Jim Gibson(CFO)

Regarding memory supply and pricing, how much is locked in for H2 2027 and what are the incremental headwinds if spot pricing holds, and when will the multi-use Smart Cells start positively impacting gross margins? - Jack Meehan (Oprah Research)

2026Q2: The SPRQ-Nx multi-use capability is expected to drive margin expansion... and become more pronounced in the latter half of 2026. - Jim Gibson(CFO)

Contradiction Point 3

Vega Demand and Pricing Outlook

Contradiction on Vega's demand predictability and ASP normalization timeline.

Mason Carrico (Stevens) - Mason Carrico (Stevens)

2026Q2: Vega demand is expected to be volatile quarter-to-quarter. The company expects ASPs to normalize in Q2. - Christian Henry(CFO)

Within the 2026 guide, how much visibility is there into consumable revenue that's baked in from the existing installed base versus new placements? - Mason Carrico (Stephens)

2026Q1: The Vega promotion was successful... The company expects ASPs to normalize in Q2. The funnel supports achieving the full-year guidance, but unit volumes may react unpredictably... - Christian Henry(CFO)

Contradiction Point 4

Financial Impact and Timeline of Spark Next Launch

Contradiction on the immediate financial benefit and gross margin improvement timeline from Spark Next.

Did Jack Meehan from Oprah Research discuss the earnings results? - Jack Meehan (Oprah Research)

2026Q2: The Spark Next ramp in H2 2026 is expected to offset persistent memory and Vega manufacturing transition costs. The company anticipates returning to gross margin improvement in 2027. - Jim Gibson(CFO)

What is the locked-in memory supply and pricing for H2 2027, including potential headwinds from spot pricing, and when will multi-use Smart Cells positively impact gross margins? - Alex D’Cason (Canaccord Genuity)

2026Q1: The launch of **SparkNext**, with its multi-use SMRT Cell, is expected to further improve economics and gross margins from the second half of 2026 into 2027. - Christian Henry(CFO)

Contradiction Point 5

Revio Consumables Pull-Through Expectations

Conflicting guidance on near-term consumables revenue growth trajectory.

What were Subbu Nambi's key insights from Guggenheim during the earnings call? - Subbu Nambi (Guggenheim)

2026Q2: Consumables revenue was flat QoQ in Q2. Expect it to remain relatively flat in Q3 as customers transition through inventory and validation, then begin to scale in the latter part of the year. - Mark Van Ollen(CRO)

What are the expectations for Revio consumables pull-through in the second half, considering population-scale sequencing and clinical accounts? - Lauren Timmins (Jefferies)

20260213-2025 Q4: Revio pull-through is expected to remain stable around $225-$250k per system. The growth is supported by expanding HiFi market and improved economics. - Christian Henry(CRO)